Targeting L1 cell adhesion molecule expression using liposomeencapsulated siRNA suppresses prostate cancer bone metastasis and growth

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9911-9929

  Sung, Shian Ying ^a,b   Wu, I Hui ^b   Chuang, Pei Hsin ^b   Petros, John A ^c,e   Wu, Hsi Chin ^d   Zeng, Hong Jie ^a   Huang, Wei Chien ^b   Chung, Leland W K ^c,f   Hsieh, Chia Ling ^a,b,c,g  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e ATLANTA VA MEDICAL CENTER   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g ASIA UNIVERSITY   (Taiwan)

Author keywords

Bone metastasis; Gene therapy; L1 cell adhesion molecule (L1CAM); Prostate cancer; Small interfering RNA (siRNA)

Indexed keywords

CELL ADHESION MOLECULE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; L1 CELL ADHESION MOLECULE; LIPOSOME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; NERVE CELL ADHESION MOLECULE L1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; CANCER INHIBITION; CANCER PATIENT; CELL INVASION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MALE; MIGRATION INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; MURINE MODEL; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING; RNA INTERFERENCE; ANIMAL; APOPTOSIS; BIOSYNTHESIS; BONE NEOPLASMS; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEURAL CELL ADHESION MOLECULE L1; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84930467771     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2478     Document Type: Article

References (66)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63(1):11-30.
2. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S and Pienta KJ. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 2000; 6(3):1038-1045.
3. McMurtry CT and McMurtry JM. Metastatic prostate cancer: complications and treatment. Journal of the American Geriatrics Society. 2003; 51(8):1136-1142.
4. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B and Blute ML. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer. 2002; 95(5):1028-1036.
5. Loberg RD, Logothetis CJ, Keller ET and Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(32):8232-8241.
6. Pauli BU, Augustin-Voss HG, el-Sabban ME, Johnson RC and Hammer DA. Organ-preference of metastasis. The role of endothelial cell adhesion molecules. Cancer metastasis reviews. 1990; 9(3):175-189.
7. Hortsch M. The L1 family of neural cell adhesion molecules: old proteins performing new tricks. Neuron. 1996; 17(4):587-593.
8. Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Gast D, Joumaa S, Zentgraf H, Fogel M and Altevogt DP. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. Faseb J. 2003; 17(2):292-294.
9. Naus S, Richter M, Wildeboer D, Moss M, Schachner M and Bartsch JW. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem. 2004; 279(16):16083-16090.
10. Lindner J, Rathjen FG and Schachner M. L1 mono- and polyclonal antibodies modify cell migration in early postnatal mouse cerebellum. Nature. 1983; 305(5933):427-430.
11. Maness PF and Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci. 2007; 10(1):19-26.
12. Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G and Schumacher U. Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer. 2002; 38(13):1708-1716.
13. Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P and Debiec H. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res. 2005; 11(3):1190-1197.
14. Miyahara R, Tanaka F, Nakagawa T, Matsuoka K, Isii K and Wada H. Expression of neural cell adhesion molecules (polysialylated form of neural cell adhesion molecule and L1-cell adhesion molecule) on resected small cell lung cancer specimens: in relation to proliferation state. J Surg Oncol. 2001; 77(1):49-54.
15. Kettunen E, Nicholson AG, Nagy B, Wikman H, Seppanen JK, Stjernvall T, Ollikainen T, Kinnula V, Nordling S, Hollmen J, Anttila S and Knuutila S. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis. 2005; 26(1):17-25.
16. Hung SC, Wu IH, Hsue SS, Liao CH, Wang HC, Chuang PH, Sung SY and Hsieh CL. Targeting l1 cell adhesion molecule using lentivirus-mediated short hairpin RNA interference reverses aggressiveness of oral squamous cell carcinoma. Molecular pharmaceutics. 2010; 7(6):2312-2323.
17. Euer NI, Kaul S, Deissler H, Mobus VJ, Zeillinger R and Weidle UH. Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep. 2005; 13(3):375-387.
18. Guo X, Xiong L, Zou L, Sun T, Zhang J, Li H, Peng R and Zhao J. L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival. Diagn Pathol. 2012; 7:96.
19. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M and Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003; 362(9387):869-875.
20. Chen DL, Zeng ZL, Yang J, Ren C, Wang DS, Wu WJ and Xu RH. L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. Journal of hematology & oncology. 2013; 6:43.
21. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C and Green JE. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res. 2002; 62(18):5325-5335.
22. Hannon GJ. RNA interference. Nature. 2002; 418(6894):244-251.
23. Tomari Y and Zamore PD. Perspective: machines for RNAi. Genes & development. 2005; 19(5):517-529.
24. Kim DH and Rossi JJ. Strategies for silencing human disease using RNA interference. Nature reviews Genetics. 2007; 8(3):173-184.
25. Bumcrot D, Manoharan M, Koteliansky V and Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature chemical biology. 2006; 2(12):711-719.
26. Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M and Altevogt P. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation. Ann Oncol. 23(7):1795-1802.
27. Drake JM, Gabriel CL and Henry MD. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis. 2005; 22(8):674-684.
28. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer. 2002; 2(6):442-454.
29. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nature reviews Molecular cell biology. 2002; 3(3):155-166.
30. Kanoh Y, Akahoshi T, Ohara T, Ohtani N, Mashiko T, Ohtani S, Egawa S and Baba S. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res. 2002; 22(3):1813-1817.
31. Karin M. Inflammation-activated protein kinases as targets for drug development. Proceedings of the American Thoracic Society. 2005; 2(4):386-390; discussion 394-385.
32. Frisch SM and Screaton RA. Anoikis mechanisms. Current opinion in cell biology. 2001; 13(5):555-562.
33. Jacobson AF and Fogelman I. Bone scanning in clinical oncology: does it have a future? European journal of nuclear medicine. 1998; 25(9):1219-1223.
34. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Trager H, Nussle K and Reske SN. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 1999; 40(10):1623-1629.
35. Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U and Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? European urology. 1998; 33(4):376-381.
36. Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer- Hofer K, Schubiger PA, Schibli R and Grunberg J. The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol. 2009; 41(7):1572-1580.
37. Stoeck A, Gast D, Sanderson MP, Issa Y, Gutwein P and Altevogt P. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol. 2007; 104(2):461-469.
38. Li Y and Galileo DS. Soluble L1CAM promotes breast cancer cell adhesion and migration in vitro, but not invasion. Cancer cell international. 2010; 10:34.
39. Sebens Muerkoster S, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, Leisner D, Kotteritzsch J, Kappes H, Kloppel G, Altevogt P, Folsch UR and Schafer H. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene. 2007; 26(19):2759-2768.
40. Held-Feindt J, Schmelz S, Hattermann K, Mentlein R, Mehdorn HM and Sebens S. The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas. Neurochemistry international. 2012; 61(7):1183-1191.
41. Kim KS, Min JK, Liang ZL, Lee K, Lee JU, Bae KH, Lee MH, Lee SE, Ryu MJ, Kim SJ, Kim YK, Choi MJ, Jo YS, Kim JM and Shong M. Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma. Clin Cancer Res. 2012; 18(11):3071-3078.
42. Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S and Altevogt P. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr. 2012; 6(4):374-384.
43. Felding-Habermann B, Silletti S, Mei F, Siu CH, Yip PM, Brooks PC, Cheresh DA, O'Toole TE, Ginsberg MH and Montgomery AM. A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple vascular and platelet integrins. J Cell Biol. 1997; 139(6):1567-1581.
44. Voura EB, Ramjeesingh RA, Montgomery AM and Siu CH. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell. 2001; 12(9):2699-2710.
45. Testa JR and Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001; 98(20):10983-10985.
46. Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J, Rivas C, Burgering BM, Serrano M and Lam EW. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem. 2000; 275(29):21960-21968.
47. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN and Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem. 1998; 273(45):29864-29872.
48. Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, Sun B, Zhang Q, Wang X, Jiang H, Krissansen GW, Qiao H and Sun X. Up-regulation of survivin by AKT and hypoxia-inducible factor 1alpha contributes to cisplatin resistance in gastric cancer. The FEBS journal. 2014; 281(1):115-128.
49. Park BK, Zeng X and Glazer RI. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res. 2001; 61(20):7647-7653.
50. Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang Y, Sein TT, Amin AR and Hamaguchi M. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis. 2000; 18(5):423-428.
51. Gavert N, Vivanti A, Hazin J, Brabletz T and Ben-Ze'ev A. L1-mediated colon cancer cell metastasis does not require changes in EMT and cancer stem cell markers. Molecular cancer research: MCR. 2011; 9(1):14-24.
52. Fischer E, Grunberg J, Cohrs S, Hohn A, Waldner-Knogler K, Jeger S, Zimmermann K, Novak-Hofer I and Schibli R. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer. Int J Cancer. 2011; 130(11):2715-2721.
53. Lee ES, Jeong MS, Singh R, Jung J, Yoon H, Min JK, Kim KH and Hong HJ. A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model. Exp Mol Med. 2012; 44(4):293-302.
54. Schafer H, Dieckmann C, Korniienko O, Moldenhauer G, Kiefel H, Salnikov A, Kruger A, Altevogt P and Sebens S. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett. 2012; 319(1):66-82.
55. Wang Y, Loers G, Pan HC, Gouveia R, Zhao WJ, Shen YQ, Kleene R, Costa J and Schachner M. Antibody fragments directed against different portions of the human neural cell adhesion molecule L1 act as inhibitors or activators of L1 function. PLoS One. 2012; 7(12):e52404.
56. Riedle S, Kiefel H, Gast D, Bondong S, Wolterink S, Gutwein P and Altevogt P. Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity. The Biochemical journal. 2009; 420(3):391-402.
57. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G and Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer biology & therapy. 2006; 5(12):1708-1713.
58. Mangala LS, Han HD, Lopez-Berestein G and Sood AK. Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42.
59. Koldehoff M, Steckel NK, Beelen DW and Elmaagacli AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clinical and experimental medicine. 2007; 7(2):47-55.
60. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464(7291):1067-1070.
61. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer discovery. 2013; 3(4):406-417.
62. Hsiao WC, Sung SY, Liao CH, Wu HC and Hsieh CL. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth. Molecular pharmaceutics. 2012; 9(5):1396-1408.
63. Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, et al. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008; 68(23):9996-10003.
64. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, Konaka H, Nakagawa M, Mousses S, Amin M, Anderson C, Johnstone P, Petros JA, Marshall FF, Zhau HE and Chung LW. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 2006; 66(19):9519-9526.
65. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW and Hsieh CL. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther. 2005; 12(4):634-643.
66. Hwang LH, Hsieh CL, Yen A, Chung YL and Chen DS. Involvement of the 5' proximal coding sequences of hepatitis C virus with internal initiation of viral translation. Biochem Biophys Res Commun. 1998; 252(2):455-460.